How should a patient with a hemoglobin A1c of 9% be managed?

Management of A1c 9.0%

For a patient with A1c 9.0%, start metformin immediately and add a second agent (GLP-1 RA or dual GIP/GLP-1 RA preferred, or SGLT2i if cardiovascular/kidney disease present) as dual combination therapy from the outset 1.

Initial Treatment Strategy

At A1c 9.0%, you are 1.5-2% above most individualized glycemic goals, which triggers the need for dual-combination therapy rather than sequential monotherapy 1, 2. The 2025 ADA guidelines explicitly state that when A1c is ≥1.5% above goal, dual therapy or a more potent agent is required to achieve and maintain target A1c 1.

First-Line Dual Combination Approach

• Metformin remains the foundation unless contraindicated (eGFR <30 mL/min/1.73 m²)

  • Start with extended-release formulation to minimize GI side effects
  • Titrate gradually to therapeutic dose
  • Monitor vitamin B12 levels periodically due to deficiency risk 1

• Add immediately as second agent:

  • GLP-1 RA or tirzepatide (dual GIP/GLP-1 RA) if weight management is a goal or cardiovascular benefit desired
  • SGLT2 inhibitor if established ASCVD, heart failure, or chronic kidney disease present
  • These agents offer superior outcomes compared to traditional stepwise approaches 1, 2

When to Consider Insulin

You do NOT need insulin at A1c 9.0% unless specific catabolic features are present 1, 2. Reserve insulin for:

• Blood glucose ≥300 mg/dL (≥16.7 mmol/L)
• A1c >10% (>86 mmol/mol)
• Symptomatic hyperglycemia (polyuria, polydipsia)
• Catabolic features: unexplained weight loss, hypertriglyceridemia, ketosis 1, 2

Important Caveat on Insulin

Research demonstrates that GLP-1 RAs can achieve equivalent or superior A1c reductions compared to insulin at baseline A1c levels of 9-11%, with the added benefits of weight loss rather than weight gain and lower hypoglycemia risk 3. The DURATION-3 and LEAD-5 studies showed GLP-1 RAs produced 0.2-0.3% greater A1c reductions than insulin glargine in patients with baseline A1c ≥9% 3.

Alternative Consideration: Short-Term Intensive Insulin (STII)

For newly diagnosed patients with A1c 9.0%, consider short-term intensive insulin therapy (2-3 weeks of basal-bolus or continuous subcutaneous insulin infusion) followed by transition to oral/injectable non-insulin agents 4. This approach:

• Rapidly reverses glucotoxicity
• Restores β-cell function and first-phase insulin secretion
• Achieves remission rates of 46-51% at 1 year in newly diagnosed patients
• Is particularly effective when diabetes duration <2 years 4

However, this is specifically for newly diagnosed patients, not those with established disease.

Monitoring and Follow-Up

• Recheck A1c in 3 months after initiating dual therapy
• Expect A1c reduction of approximately 2-2.5% with appropriate dual combination therapy 3
• Target A1c <7% for most patients, though individualize based on:
  • Life expectancy
  • Comorbidities
  • Hypoglycemia risk
  • Patient preferences

Common Pitfalls to Avoid

1. Don't use monotherapy at A1c 9.0% - you'll waste 3-6 months failing to reach goal
2. Don't reflexively start insulin - modern non-insulin agents (GLP-1 RAs, tirzepatide) are equally or more effective without weight gain and hypoglycemia
3. Don't forget to assess for comorbidities that would prioritize specific agents (ASCVD → GLP-1 RA or SGLT2i; heart failure → SGLT2i; obesity → tirzepatide or high-dose semaglutide)
4. Don't delay intensification - if not at goal in 3 months, add a third agent rather than waiting

The evidence strongly supports aggressive initial dual therapy at this A1c level rather than the outdated stepwise approach, which delays achieving glycemic control and prolongs exposure to hyperglycemia-related complications 1, 2.